*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
We established Roquefort Therapeutics plc to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders. The investment strategy of the Company is to provide Shareholders with an attractive total return achieved
primarily through capital appreciation. The Directors believe that there are numerous investment opportunities
within both private and public businesses in the medical biotech sector in the United Kingdom, Continental
Europe and Australia.
Registrars:
Key Personnel
Non-Executive Director:
Jean Duvall, Dr Darrin Disley, Simon Sinclair
Executive Chairman:
Stephen Paul West
Chief Executive Officer :
Trevor Ajanthan (Ajan) Reginald
Independent Non-Executive Director:
Michael Stein
Chief Scientific Officer:
Professor Sir Martin Evans
Contact Details
Address:
Eccleston Yards, 25 Eccleston Place, London, United Kingdom